Please login to the form below

Not currently logged in
Email:
Password:

Less pain from needles for children

Zingo, a new drug that reduces pain caused by intravenous lines in children aged three to 18 has been launched by Californian biopharmaceutical company, Anesiva
Zingo, a new drug that reduces pain caused by intravenous (IV) lines and blood draws in children aged three to 18 has been launched by Californian biopharmaceutical company, Anesiva.

The drug is an easy-to-administer powder that works within one to three minutes to relieve pain at the site of needle insertion. Currently, anaesthetic creams can take between 30 and 60 minutes to work. The need for timesaving means this application is often sacrificed at the cost of pain to the patient.

"Zingo is the first easy-to-administer, fast-acting local anaesthetic that could lead to a paradigm shift in the approach to venous access procedures such as drawing blood and placing IV lines in children," said Dr William T Zempsky who led the paediatric trials of Zingo.

Anesiva estimates that about 18 million procedures involving IV lines or blood draws are carried out on children in US hospitals each year. Many of these patients receive ongoing and multiple procedures. Zingo will offer a significant improvement in comfort for these patients.

The US Food and Drug Administration (FDA) is reviewing a supplemental New Drug Application (sNDA) to expand Zingo's indicated use to include adults. FDA action is expected by January 2009.

30th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics